Aeolus Pharmaceuticals Inc (AOLS) Financial Statements (2024 and earlier)

Company Profile

Business Address 26361 CROWN VALLEY PARKWAY, SUITE 150
MISSION VIEJO, CA 92691
State of Incorp. DE
Fiscal Year End September 30
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2017
MRQ
9/30/2016
9/30/2015
9/30/2014
9/30/2013
9/30/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 3,155941,517869281
Cash and cash equivalents 3,155941,517869281
Receivables 7501,5851,559370882
Prepaid expense and other current assets61
Other undisclosed current assets 23066472696 
Total current assets: 4,1351,7453,5481,9351,224
Noncurrent Assets
Long-term investments and receivables 3232323291
Long-term investments 3232323291
Deferred costs  21426656 
Other undisclosed noncurrent assets  (21)(426)(657)(59)
Total noncurrent assets: 3232323132
TOTAL ASSETS: 4,1671,7773,5801,9661,256
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including: 9721,5981,5525792,272
Other undisclosed accounts payable and accrued liabilities 9721,5981,5525792,272
Debt  727   
Deferred revenue and credits  22443682 
Other undisclosed current liabilities  275   
Total current liabilities: 9722,6221,9951,2612,272
Noncurrent Liabilities
Other undisclosed noncurrent liabilities     19,319
Total noncurrent liabilities:     19,319
Total liabilities: 9722,6221,9951,26121,591
Equity
Equity, attributable to parent, including: 3,195(845)1,585705(20,335)
Preferred stock  5555
Common stock 1,5201,3591,3591,346627
Additional paid in capital 191,863184,421184,223183,276159,747
Accumulated deficit (190,188)(186,630)(184,002)(183,922)(180,714)
Warrants and rights outstanding  275  19,319
Other undisclosed equity, attributable to parent  (275)  (19,319)
Total equity: 3,195(845)1,585705(20,335)
TOTAL LIABILITIES AND EQUITY: 4,1671,7773,5801,9661,256

Income Statement (P&L) ($ in thousands)

6/30/2017
TTM
9/30/2016
9/30/2015
9/30/2014
9/30/2013
9/30/2012
Revenues
(Revenue, Net)
 2,0763,1119,6313,9287,293
Cost of revenue    (555) 
Gross profit: 2,0763,1119,6313,3737,293
Operating expenses (5,349)(6,142)(9,941)(6,071)(9,664)
Other undisclosed operating income  405230  
Operating loss: (3,273)(2,626)(80)(2,698)(2,371)
Interest and debt expense (285)(2)   
Loss from continuing operations before income taxes: (3,558)(2,628)(80)(2,698)(2,371)
Income tax expense  (2)(2)(2)(2)
Loss from continuing operations: (3,558)(2,630)(82)(2,700)(2,373)
Loss before gain (loss) on sale of properties: (3,558)(2,630)(82)(2,700)(2,373)
Net loss: (3,558)(2,630)(82)(2,700)(2,373)
Other undisclosed net income (loss) attributable to parent  22(508)4,071
Net income (loss) attributable to parent: (3,558)(2,628)(80)(3,208)1,698
Other undisclosed net loss available to common stockholders, basic (2,486)    
Net income (loss) available to common stockholders, diluted: (6,044)(2,628)(80)(3,208)1,698

Comprehensive Income ($ in thousands)

6/30/2017
TTM
9/30/2016
9/30/2015
9/30/2014
9/30/2013
9/30/2012
Net loss: (3,558)(2,630)(82)(2,700)(2,373)
Comprehensive loss, net of tax, attributable to parent: (3,558)(2,630)(82)(2,700)(2,373)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: